gdc
PSSGuide_2021
Lung Cancer

Drugs for Lung Cancer

Find financial assistance programs available for lung cancer drugs.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Bristol Myers Squibb
800-861-0048

Abraxane is a microtubule inhibitor used, in combination with carboplatin, for the treatment of patients with locally advanced or metastatic non–small-cell lung cancer.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Abraxane:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Abraxane. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Abraxane, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Alecensa (alectinib)

Drug company: Genentech
866-422-2377

Alecensa is a kinase inhibitor used for the treatment of all patients with ALK-positive metastatic non–small-cell lung cancer, as detected by a specific test.

Genentech Oncology offers 2 financial assistance programs for patients using Alecensa:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Alecensa, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Alecensa free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Alimta (pemetrexed)

Drug company: Eli Lilly
866-472-8663

Alimta is a folate analog metabolic inhibitor used for the treatment of patients with locally advanced or metastatic non-squamous non–small-cell lung cancer, as an initial treatment, in combination with cisplatin, or as a maintenance treatment.

Lilly Oncology offers 2 financial assistance programs for patients using Alimta:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Alimta.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $64,400 for 1 person; $87,100 for 2 people; $109,800 for 3 people; $132,500 for 4 people; $155,200 for 5 people; and $177,900 for 6 people, this program provides Alimta at no cost.

Alunbrig (brigatinib) Tablets

Drug company: Takeda Oncology
844-817-6468

Alunbrig is a kinase inhibitor used for the treatment of patients with ALK-positive metastatic non–small-cell lung cancer, as detected by an FDA-approved test.

Takeda Oncology offers 2 financial assistance programs for patients using Alunbrig:

Takeda Oncology Co-Pay Assistance Program

Through this program, eligible patients with commercial insurance may pay no more than $10 a month for Alunbrig, with maximum assistance of $25,000 a year.

Takeda Oncology Patient Assistance Program

Patients who do not have insurance may be eligible to receive Alunbrig through this program at no cost. Patients must meet certain clinical, financial, and insurance coverage criteria.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with non-squamous non–small-cell lung cancer, in combination with carboplatin and paclitaxel.

Genentech Oncology offers 2 financial assistance programs for patients using Avastin:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Cosela (trilaciclib) Injection

Drug company: G1 Therapeutics
833-418-6663

Cosela is a CDK4/6 inhibitor used to reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer. Cosela is the first CDK4/6 inhibitor approved for use in patients with lung cancer.

G1 Therapeutics offers 2 financial assistance programs for patients using Cosela:

G1 Commercial Copay Program

Eligible patients who have commercial or private insurance may have their out-of-pocket costs for Cosela covered through this program.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Cosela at no cost through this program.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used, in combination with Tarceva, for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Cyramza is also used, in combination with docetaxel, for the treatment of patients with metastatic NSCLC whose disease progressed during or after platinum-based chemotherapy. Patients with EGFR or ALK mutations should have disease progression while receiving FDAapproved therapy for these mutations before using Cyramza.

Lilly Oncology offers 2 financial assistance programs for patients using Cyramza:

Lilly Oncology Infused Products Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 for a dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $64,400 for 1 person; $87,100 for 2 people; $109,800 for 3 people; $132,500 for 4 people; $155,200 for 5 people; and $177,900 for 6 people, this program provides Cyramza at no cost.

Exkivity (mobocertinib) Capsules

Drug company: Takeda Oncology
844-817-6468

Exkivity is an oral kinase inhibitor used for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose NSCLC progressed during or after platinum-based chemotherapy.

Takeda Oncology offers 2 financial assistance programs for patients using Exkivity:

Takeda Oncology Co-Pay Savings Program

Eligible patients with private insurance may pay as little as $0 for their Eligible patients with private insurance may pay as little as $0 for their Exkivity prescription through this program, up to a maximum annual benefit of $25,000. prescription through this program, up to a maximum annual benefit of $25,000.

Takeda Oncology Patient Assistance Program

Through this program, eligible patients who are uninsured or underinsured may receive a monthly supply of Exkivity at no cost. Qualified patients may be enrolled in this program for up to 1 year.

Gavreto (pralsetinib) Capsules

Drug company: Genentech
866-422-4377

Gavreto is an oral RET inhibitor used for the treatment of adults with metastatic non–small-cell lung cancer and RET fusions.

Genentech offers 2 financial assistance programs for patients who have been prescribed Gavreto:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gavreto, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Gavreto free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Gilotrif (afatinib) Tablets

Drug company: Boehringer Ingelheim
844-569-2836

Gilotrif is a kinase inhibitor used as a first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations. Gilotrif is also used for patients with metastatic squamous NSCLC, and as first-line treatment for patients with metastatic NSCLC and non-resistant EGFR mutations L861Q, G719X, and S768I.

Boehringer Ingelheim offers 4 financial assistance programs for patients using Gilotrif.

Gilotrif Plus Co-pay Assistance Program

This program ensures that commercially insured patients pay an out-of-pocket cost of $0 monthly for Gilotrif. This program has no income eligibility, benefit cap, or any additional paperwork requirements.

Gilotrif Bridge Program

The Bridge Program offers eligible commercially insured patients who are experiencing a delay of more than 5 days of insurance approval a 15-day free supply of Gilotrif for an FDA-approved indication.

Gilotrif Dose Exchange Program

This program facilitates the transition to a new dose of Gilotrif at no cost to eligible commercially insured patients, and eliminates an additional copay for Gilotrif for 1 month.

BI Cares Foundation Patient Assistance Program

This program offers free treatment with Gilotrif to eligible, uninsured, or underinsured Medicare patients who have been denied financial assistance from other foundations.

Hycamtin (topotecan) Injection

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used for the treatment of patients with small-cell lung cancer and platinum-sensitive disease progressing after first-line chemotherapy.

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Hycamtin for free until prescription drug coverage becomes available to them.

Imfinzi (durvalumab)

Drug company: AstraZeneca
844-275-2360

Imfinzi is a PD-L1 inhibitor used to reduce the risk of cancer progression in patients with stage III non–small-cell lung cancer whose tumor cannot be removed surgically (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Imfinzi:

Imfinzi Co-pay Savings Program

Patients with private insurance will pay $0 per infusion of Imfinzi; this program pays the remaining out-of-pocket costs up to a maximum of $26,000 annually, with a program maximum of $100 per infusion assistance. Residents of Massachusetts, Michigan, Minnesota, and Rhode Island are not eligible for this assistance.

AZ&Me Prescription Savings Program

This prescription savings program offers free Imfinzi to qualifying patients without insurance, those who have Medicare Part D coverage, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in limited income subsidy for Medicare Part D, and/or a life-changing event in the past year that affected finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Imfinzi (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Iressa (gefitinib)

Drug company: AstraZeneca
844-275-2360

Iressa is a tyrosine kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer that is associated with EGFR exon 19 deletions or exon 21 substitution mutations.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Iressa:

IRESSA Co-pay Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay no more than $0 per dose of Iressa, with a maximum savings of $26,000 annually. Eligible patients must have private health insurance that partially covers the medication costs for Iressa.

AZ&Me Prescription Savings Program

This prescription savings program offers free Iressa to qualifying patients without insurance, those who have Medicare Part D coverage, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in limited income subsidy for Medicare Part D, and/or a life-changing event in the past year that affected finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of Iressa (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used as a single agent for the first-line treatment of patients with metastatic or stage III non-resectable non–small-cell lung cancer (NSCLC) with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; for patients with metastatic NSCLC expressing PD-L1, as determined by an FDA-approved test, and disease progression during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression with an FDA-approved therapy for these mutations before using Keytruda. Keytruda is also used, in combination with pemetrexed and platinum, as first-line treatment of patients with metastatic non-squamous NSCLC; in combination with carboplatin and paclitaxel or Abraxane, as first-line treatment of patients with metastatic squamous NSCLC and no EGFR or ALK mutations, and for the treatment of patients with metastatic small-cell lung cancer whose disease progressed during or after platinum-based chemotherapy and at least 1 other line of therapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have a household income of $64,400 or less for individuals, $87,100 or less for couples, or $132,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for medicines, may request that an exception be made, provided their household income is not above a set limit.

Libtayo (cemiplimab-rwlc) Injection

Drug company: Regeneron/Sanofi Genzyme
877-542-8296

Libtayo is a PD-1 inhibitor used for the first-line treatment of non–small-cell lung cancer (NSCLC) that is associated with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR, ALK, or ROS1 aberrations, either in patients with locally advanced NSCLC who are not candidates for surgical resection or for definitive chemoradiation therapy, or in patients with metastatic NSCLC.

Regeneron and Sanofi Genzyme, through Libtayo Surround, offer 2 financial assistance programs for patients who have been prescribed Libtayo:

Libtayo Surround Commercial Copay Program

Eligible patients who have private insurance may pay $0 for Libtayo, including copay, co-insurance, and insurance deductibles, with maximum assistance of $25,000 annually.

Libtayo Surround Patient Assistance Program

Patients who meet this program’s income requirements may receive Libtayo at no cost if they are uninsured, underinsured, or have Medicare Part B coverage with no supplemental insurance. To qualify for this program, patients must have an annual gross household income that does not exceed the greater of $100,000 or 500% of the federal poverty level.

Lorbrena (lorlatinib)

Drug company: Pfizer
877-744-5675

Lorbrena is a kinase inhibitor used for the first-line treatment of patients with non–small-cell lung cancer (NSCLC) and ALK mutations. Lorbrena is also used for the treatment of patients with metastatic NSCLC and ALK mutation that has progressed with crizotinib therapy and at least one other ALK inhibitor for metastatic disease; or progressed with alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Lorbrena:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Lorbrena is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Lorbrena for free or at a savings. Eligible patients with government insurance may also receive Lorbrena for free if they cannot find independent charitable foundation support.

Lumakras (sotorasib) Tablets

Drug company: Amgen
888-427-7478

Lumakras is the first KRAS G12C inhibitor used for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and KRAS G12C mutation, as determined by an FDA-approved test, after 1 or more systemic therapies.

Amgen Assist 360 offers 2 financial assistance programs for patients using Lumakras:

Amgen FIRST STEP Program

With this program, eligible patients who have commercial or private insurance will pay $0 for the first dose of Lumakras and $5 for each subsequent dose. Call Amgen First Step to receive information regarding eligibility and the relevant maximum program benefit.

Amgen Safety Net Foundation

Eligible patients who are underinsured or uninsured may receive Lumakras at no cost through this program.

Mekinist (trametinib) & Tafinlar (dabrafenib)

Drug company: Novartis
800-245-5356

Mekinist and Tafinlar are kinase inhibitors that are used in combination for the treatment of patients with metastatic non–small-cell lung cancer with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using the combination of Mekinist and Tafinlar:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance for the Mekinist and Tafinlar combination. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Mekinist and Tafinlar for free until prescription drug coverage becomes available to them.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used for the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small-cell lung cancer, in combination with carboplatin and paclitaxel.

Amgen offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum benefit of $20,000 per year.

Amgen Safety Net Foundation

Patients with limited or with no drug insurance coverage, and patients with Medicare Part D insurance who satisfy the income eligibility requirements may receive Mvasi for free.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used, in combination with Yervoy, for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) expressing PD-L1, as determined by an FDA-approved test, and no EGFR or ALK genomic tumor aberrations; treatment, in combination with Yervoy and 2 cycles of platinum-doublet chemotherapy, of adults with metastatic or recurrent NSCLC and no EGFR or ALK mutations; and in combination with Yervoy, for the first-line treatment of adults with unresectable malignant pleural mesothelioma, a cancer of the lining of the lungs. Opdivo is also used alone for the treatment of patients with metastatic NSCLC that progressed during or after platinum-based chemotherapy; patients with EGFR or ALK mutations should have disease progression during an FDA-approved therapy for these mutations before receiving Opdivo.

Bristol Myers Squibb Access Support provides 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with the out-ofpocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Photofrin (porfimer)

Drug company: Pinnacle Biologics
855-215-2720

Photofrin is used for the treatment of patients with microinvasive endobronchial non–small-cell lung cancer (NSCLC). Photofrin is also used to treat patients with completely or partially obstructing endobronchial NSCLC.

Pinnacle Biologics offers 1 financial assistance program for patients using Photofrin:

Photofrin Patient Assistance Program

This program is designed to assist financially disadvantaged patients who have no prescription coverage. Eligible patients must have an annual household income at or below 200% of the federal poverty level.

Portrazza (necitumumab)

Drug company: Eli Lilly
866-472-8663

Portrazza is an EGFR antagonist used as first-line treatment, in combination with gemcitabine and cisplatin, for patients with metastatic squamous non–small-cell lung cancer.

Lilly Oncology offers 2 financial assistance programs for patients using Portrazza:

Lilly Oncology Infused Products Co-pay Program

For privately insured patients whose household income does not exceed $100,000 or 500% of the federal poverty level, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose for Portrazza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance, or those whose insurance does not cover therapy, and a household income at or below 500% of the federal poverty level, this program provides Portrazza at no cost.

Retevmo (selpercatinib) Capsules

Drug company: Eli Lilly
866-472-8663

Retevmo is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer and RET mutations or fusions.

Lilly Oncology offers 2 financial assistance programs for patients who have been prescribed Retevmo:

Retevmo Savings Card

Eligible patients who have private insurance may pay as little as $0 for a 30-day supply of Retevmo, subject to a monthly cap of wholesale acquisition cost plus pharmacy charges and a maximum annual benefit of $25,000.

Lilly Cares Foundation Patient Assistance Program

For eligible patients who are uninsured or underinsured, and who have a household income at or below 500% of the federal poverty level, this program provides Retevmo for free.

Rozlytrek (entrectinib) Capsules

Drug company: Genentech
866-422-2377

Rozlytrek is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer and a ROS1 mutation, as determined by an FDA-approved test.

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Rozlytrek:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Rozlytrek, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rozlytrek free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Rybrevant (amivantamab-vmjw) Injection

Drug company: Janssen Biotech
833-792-7382

Rybrevant is a first bispecific EGFR-directed and MET receptor-directed antibody approved for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutation (as detected by an FDA-approved test) whose NSCLC has progressed during or after platinum-based chemotherapy.

Janssen Biotech, through Janssen CarePath, offers 1 financial assistance program for patients using Rybrevant:

Janssen CarePath Savings Program

Eligible patients who have private insurance pay as little as $5 for each infusion of Rybrevant, with a $26,000 maximum annual benefit.

Tabrecta (capmatinib) Tablets

Drug company: Novartis
800-282-7630

Tabrecta is a kinase inhibitor used for the treatment of adults with metastatic non–small-cell lung cancer.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients who have been prescribed Tabrecta:

Novartis Oncology Universal Co-pay Program

Through this program, patients with private insurance may pay $0 monthly for Tabrecta. The program pays the remaining balance for Tabrecta until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Eligible patients without insurance who are US citizens may receive Tabrecta for free until a prescription drug coverage becomes available to them. To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements.

Tabrecta 14-Day Free Trial Program

With this program, eligible patients can receive a free 14-day supply of Tabrecta.

Tagrisso (osimertinib)

Drug company: AstraZeneca
844-275-2360

Tagrisso is a kinase inhibitor used as adjuvant therapy, after tumor resection in adults with non–small-cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, and for the first-line treatment of patients with NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. Tagrisso is also used for the treatment of patients with metastatic NSCLC and EGFR T790M mutation, as detected by an FDA-approved test.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Tagrisso:

Tagrisso Co-pay Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay no more than $0 monthly for Tagrisso, with a maximum savings of $26,000 annually. Eligible patients must have private health insurance that partially covers medication costs for Tagrisso.

AZ&Me Prescription Savings Program

This prescription savings program offers free Tagrisso to qualifying patients without insurance, those who have Medicare Part D coverage, and those who receive Tagrisso through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in Medicare’s limited income subsidy, and/or a life-changing event in the past year that affected their finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll), and a supply of Tagrisso (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Tarceva (erlotinib) Tablets

Drug company: Genentech
866-422-2377

Tarceva is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, in patients whose cancer is progressing after at least 1 previous chemotherapy regimen.

Genentech Oncology offers 2 financial assistance programs for patients using Tarceva:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Tarceva, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tarceva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and high PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations; treatment of patients with metastatic NSCLC that progressed after FDA-approved therapies; in combination with Abraxane and carboplatin for first-line treatment of adults with metastatic non-squamous NSCLC and no EGFR or ALK mutations; and in combination with carboplatin and etoposide, for first-line treatment of adults with extensive-stage small-cell lung cancer. Tecentriq is also used, in combination with Avastin and chemotherapy, as first-line treatment, for patients with metastatic non-squamous NSCLC and no EGFR or ALK mutations; and for the adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II to stage IIIA NSCLC.

Genentech Oncology offers 2 financial assistance programs for patients using Tecentriq:

Genentech Oncology Co-pay Assistance Program

Patients with private insurance will pay just a $5 copay per prescription of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Tepmetko (tepotinib) Tablets

Drug company: EMD Serono
844-662-3631

Tepmetko is the first MET kinase inhibitor drug conjugate approved for the treatment of adults with metastatic non–small-cell lung cancer and MET exon 14 skipping alterations.

EMD Serono offers 3 financial assistance programs for patients using Tepmetko:

ONC Co-Pay Assistance Program

Eligible patients who have private insurance may pay as little as $0 co-pay for each prescription of Tepmetko, with up to a maximum annual program benefit of $15,000.

ONC Patient Assistance Program

Eligible patients who are uninsured or underinsured, and who meet certain income and residency requirements, may receive Tepmetko at no cost through this program.

Bridge Program

Eligible patients who experience a delay in their insurance coverage for at least 5 days can receive their initial prescription of Tepmetko free of charge.

Vizimpro (dacomitinib)

Drug company: Pfizer
877-744-5675

Vizimpro is a kinase inhibitor used as a first-line treatment for patients with metastatic non–small-cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutations.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Vizimpro:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Vizimpro is no more than $25, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Vizimpro for free or at a savings. Eligible patients with government insurance may also receive Vizimpro for free if they cannot find independent charitable foundation support.

Xalkori (crizotinib) Capsules

Drug company: Pfizer
877-744-5675

Xalkori is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer with ALK or ROS1 mutation.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Xalkori:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients who have private insurance so that their copay for Xalkori is $0 monthly, with a maximum savings of $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are uninsured and patients with government insurance. Uninsured patients may qualify to receive Xalkori for free, or at a savings. Eligible patients with government insurance who cannot find independent charitable foundation support, may receive Xalkori for free.

Yervoy (ipilimumab)

Drug company: Bristol Myers Squibb
800-861-0048

Yervoy is a human CTLA-4-blocking antibody used, in combination with Opdivo, for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) expressing PD-L1, as determined by an FDA-approved test, and no EGFR or ALK mutations. Yervoy is also used, in combination with Opdivo and 2 cycles of platinum-doublet chemotherapy, for the treatment of adults with metastatic or recurrent NSCLC and no EGFR or ALK mutations; and in combination with Opdivo, for the first-line treatment of adults with unresectable malignant pleural mesothelioma, a cancer of the lining of the lungs.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients who have been prescribed Yervoy:

BMS Oncology Co-pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or co-insurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay $25 copay, and BMS covers the remaining amount, up to $25,000 annually per product (or $50,000 annually for 2 BMS products administered in combination).

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Yervoy, may be eligible for help paying for Yervoy if they are receiving treatment as an outpatient and have an annual income of less than 300% of the federal poverty level.

Zepzelca (lurbinectedin) Injection

Drug company: Jazz Pharmaceuticals
833-533-5299

Zepzelca is an alkylating drug used for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy.

Jazz Pharmaceuticals offers 2 financial assistance programs for patients who have been prescribed Zepzelca:

JazzCares Copay Savings Card Program

Eligible patients who have private insurance may pay as little as $10 for Zepzelca, subject to an annual maximum.

JazzCares Patient Assistance Program

Patients who are uninsured or underinsured and who have a household gross income of less than 400% of the federal poverty level may receive Zepzelca at no cost through this program.

Zirabev (bevacizumab-bvzr)

Drug company: Pfizer
877-744-5675

Zirabev, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with carboplatin and paclitaxel, for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non–small-cell lung cancer.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Zirabev is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Zirabev for free or at a savings. Eligible patients with government insurance may also receive Zirabev for free if they cannot find independent charitable foundation support.

Zykadia (ceritinib)

Drug company: Novartis
800-245-5356

Zykadia is a kinase inhibitor used for the treatment of patients with metastatic non–small-cell lung cancer and ALK mutation, as detected by an FDA-approved test.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Zykadia:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance for Zykadia. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

For patients without insurance, to be eligible for financial assistance through this program, a patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Zykadia for free until prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Lung Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Cosela (trilaciclib) Injection
  • Drug company
  • G1 Therapeutics
  • Indication
  • To reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer
  • Patient support services
  • G1 Commercial Copay Program
    833-418-6663

    Patient Assistance Program
    833-418-6663
    Drug name (generic name)
  • Cyramza (ramucirumab)
  • Drug company
  • Eli Lilly
  • Indication
  • First-line treatment, in combination with Tarceva, of metastatic NSCLC and EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

    Treatment, in combination with docetaxel, of metastatic NSCLC whose disease progressed during or after platinum-based chemotherapy
  • Patient support services
  • Lilly Oncology Infused Products Co-pay Program
    866-472-8663

    Lilly Cares Foundation Patient Assistance Program
    800-545-6962
    Drug name (generic name)
  • Exkivity (mobocertinib) Capsules
  • Drug company
  • Takeda Oncology
  • Indication
  • Treatment of adults with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose NSCLC progressed during or after platinum-based chemotherapy
  • Patient support services
  • Takeda Oncology Co-Pay Assistance Program
    844-817-6468

    Takeda Oncology Patient Assistance Program
    844-817-6468
    Drug name (generic name)
  • Hycamtin (topotecan) injection
  • Drug company
  • Novartis
  • Indication
  • Small-cell lung cancer with platinum-sensitive disease progressing after first-line chemotherapy
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • First-line treatment of metastatic or stage III non-resectable NSCLC with high PD-L1 and no EGFR or ALK mutations

    Metastatic NSCLC expressing PD-L1 and disease progression during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression during an FDA-approved therapy for these mutations before using Keytruda

    Metastatic non-squamous NSCLC, as first-line treatment, in combination with carboplatin and paclitaxel or Abraxane

    First-line treatment, in combination with pemetrexed and platinum, of metastatic non-squamous NSCLC and no EGFR or ALK mutations

    Treatment of metastatic small-cell lung cancer progressing during or after platinum-based chemotherapy and at least 1 other therapy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400
    Drug name (generic name)
  • Libtayo (cemiplimab-rwlc) Injection
  • Drug company
  • Regeneron/Sanofi Genzyme
  • Indication
  • First-line treatment of NSCLC with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR, ALK, or ROS1 aberrations in patients with locally advanced NSCLC who are not candidates for surgical resection or for definitive chemoradiation therapy

    First-line treatment of NSCLC with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR, ALK, or ROS1 aberrations in patients with metastatic NSCLC
  • Patient support services
  • Libtayo Surround Commercial Copay Program
    877-542-8296

    Libtayo Surround Patient Assistance Program
    877-542-8296
    Drug name (generic name)
  • Lumakras (sotorasib) Tablets
  • Drug company
  • Amgen
  • Indication
  • Treatment of adults with locally advanced or metastatic NSCLC and KRAS G12C mutation after 1 or more systemic therapies
  • Patient support services
  • Amgen FIRST STEP Program
    888-427-7478

    Amgen Safety Net Foundation
    888-762-6436
    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • First-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436
    Drug name (generic name)
  • Opdivo (nivolumab)
  • Drug company
  • Bristol Myers Squibb
  • Indication
  • First-line treatment, in combination with Yervoy, of metastatic NSCLC and PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations

    Treatment, in combination with Yervoy and 2 cycles of chemotherapy, of metastatic or recurrent NSCLC and no EGFR or ALK mutations

    Treatment of metastatic NSCLC that progressed during or after platinum-based chemotherapy

    First-line treatment, in combination with Yervoy, of unresectable malignant pleural mesothelioma (cancer of the lining of the lungs)
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003
    Drug name (generic name)
  • Rybrevant (amivantamab-vmjw) Injection
  • Drug company
  • Janssen Biotech
  • Indication
  • Treatment of adults with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutation whose NSCLC progressed during or after platinum-based chemotherapy
  • Patient support services
  • Janssen CarePath Savings Program
    833-792-7382
    Drug name (generic name)
  • Tagrisso (osimertinib)
  • Drug company
  • AstraZeneca
  • Indication
  • Adjuvant therapy after tumor resection of NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test

    First-line or adjuvant treatment of patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations

    Metastatic NSCLC with EGFR T790M mutation
  • Patient support services
  • Tagrisso Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    844-275-2360
    Drug name (generic name)
  • Tarceva (erlotinib) Tablets
  • Drug company
  • Genentech
  • Indication
  • Treatment of metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, in patients whose cancer is progressing after at least 1 previous chemotherapy regimen
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • First-line treatment of metastatic NSCLC and high PD-L1 expression, as determined by an FDAapproved test, and no EGFR or ALK mutations

    Treatment of metastatic NSCLC that progressed during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression with FDA-approved therapy for NSCLC and these mutations before receiving Tecentriq

    First-line treatment, in combination with Avastin and chemotherapy, for metastatic non-squamous NSCLC and no EGFR or ALK mutations

    First-line treatment of metastatic nonsquamous NSCLC and no EGFR or ALK mutations, in combination with Abraxane and carboplatin

    First-line treatment of extensive-stage small-cell lung cancer, in combination with carboplatin and etoposide

    Adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II-IIIA NSCLC
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331
    Drug name (generic name)
  • Yervoy (ipilimumab)
  • Drug company
  • Bristol Myers Squibb
  • Indication
  • First-line treatment, in combination with Opdivo, of metastatic NSCLC and PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations

    Treatment, in combination with Opdivo and 2 cycles of chemotherapy, of metastatic or recurrent NSCLC and no EGFR or ALK mutations

    Treatment of metastatic NSCLC that progressed during or after platinum-based chemotherapy

    First-line treatment, in combination with Opdivo, of unresectable malignant pleural mesothelioma (cancer of the lining of the lungs)
  • Patient support services
  • BMS Oncology Co-pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003
NSCLC indicates non–small-cell lung cancer.

Share this:

Last modified: March 17, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests